Geron Corp (GERN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments

GuruFocus News

Thu, February 26, 2026 at 4:02 AM GMT+9 3 min read

In this article:

GERN

-15.38%

This article first appeared on GuruFocus.

**Q4 2025 Net Revenue:** $48 million.

**Full Year 2025 Net Revenue:** $184 million.

**Q4 2025 Demand Growth for RYTELO:** 9% compared to Q3 2025.

**Full Year 2025 Operating Expenses:** Approximately $255 million.

**2026 Net Revenue Guidance for RYTELO:** $220 million to $240 million.

**2026 Operating Expenses Guidance:** $230 million to $240 million.

**Cash and Equivalents as of December 31, 2025:** Approximately $400 million.

**Research & Development Expenses for 2025:** $74 million.

**Selling, General & Administrative Expenses for 2025:** $159 million.

Warning! GuruFocus has detected 8 Warning Signs with GERN.

Is GERN fairly valued? Test your thesis with our free DCF calculator.

Release Date: February 25, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

RYTELO's fourth quarter net revenue was $48 million, aligning with expectations and contributing to a full-year revenue of $184 million, marking a successful first full commercial year.

Geron Corp (NASDAQ:GERN) projects RYTELO net revenue for 2026 to be between $220 million and $240 million, indicating anticipated growth.

The company has streamlined operations, reducing projected 2026 operating expenses by approximately $20 million compared to 2025.

Geron Corp (NASDAQ:GERN) has a strong balance sheet with approximately $400 million in cash and marketable securities, providing financial flexibility.

The strategic restructuring and commercial strategy are designed to enhance RYTELO's market presence, particularly in the second-line lower-risk MDS segment.

Negative Points

Total operating expenses for 2025 were $255 million, which is high relative to the revenue generated.

Despite revenue growth, the company is not focused on achieving profitability in 2026, prioritizing investment in commercial strategies instead.

There is uncertainty regarding the European market strategy due to complexities in HTA processes and MFN pricing impacts.

The company faces challenges in expanding its market presence, needing to increase both the number of prescribing accounts and repeat prescriptions.

Geron Corp (NASDAQ:GERN) must navigate competitive pressures in the second-line treatment space, particularly with the shift of luspatercept to the first-line setting.

Q & A Highlights

Q: Can you provide specifics on the commercial or physician behavioral milestones to watch for in the first half of the year to ensure the growth inflection is on track? A: Harout Semerjian, CEO, emphasized the importance of Q4’s 9% demand growth as a forward-looking metric. The company is focused on executing refined messaging and targeting high-volume accounts to achieve the projected revenue growth of $220 million to $240 million for 2026.

Story Continues  

Q: What is the current focus on second-line patients, and how does it compare to third-line patients? A: Harout Semerjian, CEO, stated that Geron is targeting approximately 8,000 second-line patients in the lower-risk MDS category. The focus is on second-line patients transitioning from first-line treatments like luspatercept, with RYTELO positioned as a preferred second-line agent.

Q: How does the 9% demand growth and 15% increase in prescribing accounts translate into revenue? A: Harout Semerjian, CEO, explained that demand growth is key, with efforts focused on high-volume community accounts. The strategy aims for consistent quarter-over-quarter growth in demand, which will drive revenue.

Q: What is the potential number of ordering accounts for the 8,000 second-line patients, and is there a path to profitability in 2026? A: Harout Semerjian, CEO, noted significant potential in community accounts, which represent 80% of the market. Michelle Robertson, CFO, mentioned that while there is a path to profitability, the focus for 2026 is on strategic investments to drive impact.

Q: What are the plans for European approval and the ex-US strategy? A: Harout Semerjian, CEO, stated that while European approval is secured, the focus is on understanding HTA processes and negotiating pricing. The company is engaging with potential partners to explore commercialization opportunities in Europe.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Terms and Privacy Policy

Privacy Dashboard

More Info